ACR Convergence 2023

November 10-15, 2023. San Diego, CA.

View by Number View by Title View Sessions

Sunday, November 12, 2023

4:00PM-5:30PM: Abstract Number: 0808

Real-World Disease Monitoring Patterns in Rheumatoid Arthritis-Associated Interstitial Lung Disease in the Veterans Affairs Health Care System

Abstracts: Health Services Research I

4:00PM-5:30PM: Abstract Number: 0855

Real-world Experience with Avacopan in ANCA Vasculitis: A Multi-center Retrospective Cohort Analysis

Abstracts: Vasculitis – ANCA-Associated I

4:00PM-5:30PM: Abstract Number: 0819

Regression to the Mean for Physical Function and Quality of Life in Trials for Symptomatic Knee Osteoarthritis

Abstracts: Osteoarthritis I: Clinical Trials

4:00PM-5:30PM: Abstract Number: 0796

Role of Group 2 Innate Lymphoid Cells in the Pathogenesis of Rheumatoid Arthritis

Abstracts: RA – Animal Models

4:00PM-5:30PM: Abstract Number: 0852

Screening for Specific Antinuclear Antibodies Using an Artificial Intelligence-enabled Antinuclear Antibody HEp-2 Substrate by Indirect Immunofluorescence Assay

Abstracts: SLE – Diagnosis, Manifestations, & Outcomes I: Biomarkers

4:00PM-5:30PM: Abstract Number: 0823

Sleep Disturbance Predicts Pain Interference in Patients with Early Rheumatoid Arthritis in a Prospective Real-World Cohort

Abstracts: Patient Outcomes, Preferences, & Attitudes I: Assessment Tools

4:00PM-5:30PM: Abstract Number: 0813

Sonographic Crystal Deposits and Power-Doppler Signal in Patients with Gout Fulfilling Remission Criteria: A Multicenter Study Enrolling 115 Participants

Abstracts: Metabolic & Crystal Arthropathies – Basic & Clinical Science

4:00PM-5:30PM: Abstract Number: 0841

Spondyloarthritis Research and Treatment Network (SPARTAN) Draft Referral Recommendations for Axial Spondyloarthritis

Abstracts: Spondyloarthritis Including Psoriatic Arthritis – Diagnosis, Manifestations, & Outcomes I: AxSpA

4:00PM-5:30PM: Abstract Number: 0802

Targeting Fibroblasts in Inflammatory Disease Using Engineered T Cells

Abstracts: T Cell Biology & Targets in Autoimmune & Inflammatory Disease

4:00PM-5:30PM: Abstract Number: 0810

Telehealth Utilization and Satisfaction Among Patients with Rheumatic Diseases: Trends Since the Onset of the COVID-19 Pandemic

Abstracts: Health Services Research I

4:00PM-5:30PM: Abstract Number: 0793

The Dual Specificity Phosphatase 6 (DUSP6) Regulates Arthritis Severity and IL10 Production

Abstracts: RA – Animal Models

4:00PM-5:30PM: Abstract Number: 0795

The Focal Adhesion Protein Lasp1 Links the Arp2/3 Complex to Cell-to-cell Contact Formation in Arthritic Fibroblast-like Synoviocytes

Abstracts: RA – Animal Models

4:00PM-5:30PM: Abstract Number: 0830

The Upregulation of MAP Kinase Pathway Genes Is Associated with Poor Treatment Response to Tofacitinib in Polyarticular Course Juvenile Idiopathic Arthritis

Abstracts: Pediatric Rheumatology – Clinical I: JIA

4:00PM-5:30PM: Abstract Number: 0845

The Yield of Repeated Assessments in Chronic Back Pain Patients Suspected of Early Axial Spondyloarthritis: Two-year Data from the SPondyloArthritis Caught Early (SPACE) Cohort

Abstracts: Spondyloarthritis Including Psoriatic Arthritis – Diagnosis, Manifestations, & Outcomes I: AxSpA

4:00PM-5:00PM: Abstract Number: PP15

Toward a Frontier Beyond the Barriers of Position and Prejudice

Patient Perspectives

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].